feed,title,long_url,short_url
Benzinga,"Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst",https://benzinga.com/analyst-ratings/analyst-color/24/07/39696780/eli-lillys-3-2b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attent,https://da.gd/ctT3G
